链激酶和重组链激酶治疗急性心肌梗死的疗效比较──附63例报告　

Comparison of clinical effects between streptokinase and recombinant－streptokinase in the treatment of acute myocardial infarction：with 63 cases report．

目的：比较链激酶和重组链激酶治疗急性心肌梗死的疗效和安全性。方法：发病12小时内的63例急性心肌梗死病人， 分别予链激酶150 万单位(31例)或重组链激酶150 万单位(32例)溶于5％葡萄糖液100 mL内静脉滴注60分钟， 观察冠状动脉再通率、病死率和不良反应等的发生情况。结果：链激酶组和重组链激酶组的冠状动脉再通率分别为61％和72％（P ＜0．01），病死率均为6％； 过敏反应发生率分别为13％ 和6％；轻微出血并发症发生率分别为19％ 和16％。结论：链激酶和重组链激酶治疗急性心肌梗死均安全有效，不良反应少， 重组链激酶的疗效优于链激酶，不良反应少于链激酶。

 Objective： To compare the clinical efficacy and safety of streptokinase(SK) and recombinant－streptokinase(rSK) in the treatment of acute myocardial infarction(AMI)． Methods：1．5 MU of SK (31 cases ) or rSK( 32 cases ) in 100 mL of 5％ glucose solution was intravenously dripped into the patients with AMI within 60 min respectively． The reperfusion rate of infarcted related coronary artery(IRA) cardiac events and adverse reactions were observed． Results： The reperfusion rate of IRA was 61％ in SK group and 72％ in rSK group(P ＜0．01)． Mortality of the patient was 6％ in both group． Adverse reaction rate was 13％ in SK group and 6％ in rSK group while mild bleeding rate was 19％ and 16％ respertively． Conclusion：SK and rSK are effective and safe in the treatment of AMI． Administration rSK has higher reperfusion rate of IRA and fewer adverse reactions．